Milestone Pharmaceuticals' stock drops over 61% after receiving a Complete Response Letter from the FDA for its CARDAMYST NDA ...

Cramer stated on Mad Money at the end of last week's trading that Recursion's stock performance has "been disastrous" since the company's management appeared on his program in May 2024. He added, ...

Key Takeaway Bayer was ordered to pay more than $2 billion by a jury in a Georgia state court in the latest legal case ...

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and BioCryst Pharmaceuticals wasn’t one of them. The 10 stocks ...

Around the middle of February, shares of Recursion Pharmaceuticals bounded higher after the company reported phase 2 results for its former lead candidate. Unfortunately, the stock fell by 40.5% ...

West Pharmaceutical faces challenges from peer ResMed Inc. (RMD), which has reported 9.4% gains on a six-month basis and 14.9% returns over the past year. Nevertheless, the stock has a consensus ...

With a market cap of $124.9 billion, Vertex Pharmaceuticals Incorporated (VRTX ... 200-day moving averages since last year. Also, the stock stayed above its 50-day moving average during the ...

Argus has a "buy" rating and $185 price target for JNJ stock, which closed at $146.64 on Jan. 23. AbbVie is a global pharmaceutical company. Its key drugs include Humira for treating rheumatoid ...